On September 2, ScanSource (NASDAQ:SCSC) completed its all-cash acquisition of MicroAge, a $220.5 million deal that closed just two weeks after it was first announced on August 20. The timing lines up with a fourth quarter that already showed ScanSource growing faster than it has in years, with net sales up 17.3% and non-GAAP earnings per share climbing more than 43%. Layering an IT solutions integrator with roughly 2,400 clients onto that momentum raises the question of whether the combination adds as much as ScanSource is promising.
A Deal Built For Margins
ScanSource’s fourth quarter gave management plenty to point to. Net sales for the three months ended June 30 rose 17.3% year over year to $953.1 million, and gross profit climbed 14% to $119.8 million. Diluted GAAP earnings per share jumped from $0.88 to $1.24, while the non-GAAP figure rose from $1.02 to $1.46, a sign the top-line growth is reaching shareholders rather than being absorbed by costs. For the full fiscal year, net sales reached $3.23 billion and adjusted EBITDA rose to $151.5 million.
MicroAge is meant to build on that. The company brings managed services, cybersecurity, cloud and data center work to a distributor that has historically made its money moving hardware, and ScanSource has said the deal should lift gross margin, EBITDA margin and non-GAAP earnings per share within its first year, plus turn free cash flow positive on top of what ScanSource already generates. Recurring revenue already made up 33.7% of ScanSource’s gross profit in fiscal 2026, up from 32.8% the year before, and folding in an integrator with more than 200 employees gives that recurring base another leg. ScanSource also produced $113.8 million of free cash flow in fiscal 2026 and still found room to repurchase $97.9 million of stock, evidence that the balance sheet had capacity before the MicroAge cash flow even shows up.
Borrowed Money, Bigger Bets
The deal was not paid for with cash on hand. ScanSource drew on its existing credit facility to cover the $220.5 million purchase price, adding to a balance sheet that carried $101.4 million of total debt and $88.4 million of cash as of June 30. That means the new borrowing alone is more than double what the company held in debt just a couple of months earlier, and integration costs on an IT services business run differently than the hardware distribution ScanSource already knows.
The fourth quarter numbers also had a soft spot. Gross profit margin actually slipped to 12.6% from 12.9% a year earlier, even as the specialty technology solutions segment carried 17.6% growth. ScanSource’s smaller Intelisys & Advisory segment, which includes higher-margin advisory work, grew only 7.2% in the quarter and 3.1% for the full year, trailing the hardware-heavy core business by a wide margin. Fiscal 2027 guidance of 6% to 10% net sales growth and $158 million to $165 million of adjusted EBITDA was issued on August 20, before the MicroAge deal closed, and specifically excludes it, so investors do not yet have management’s own numbers for what the combined company should produce.
What The Market Is Pricing In
Hedge fund ownership of ScanSource rose from 16 funds to 20 in the most recent quarter, pointing to growing institutional interest heading into the MicroAge deal. Short interest sits at 6.73% of the float, a level that suggests a real but not overwhelming bear camp. The stock trades at a forward price-to-earnings ratio of 11.95 as of September 15, cheap enough that the market does not appear to be pricing in much of the growth ScanSource just delivered. That combination of rising fund ownership and a still-modest multiple leaves room for the stock to re-rate if the MicroAge integration goes smoothly.
Where This Leaves Investors
ScanSource closed out fiscal 2026 with double-digit sales growth, then used borrowed money rather than cash to add MicroAge’s services business to the mix. The bull case rests on MicroAge turning ScanSource’s hardware relationships into recurring, higher-margin revenue the way management projects. The bear case rests on that borrowed capital and on fiscal 2027 guidance that still excludes the deal entirely. For the optimistic view to hold, the promised margin and EPS accretion needs to show up fast.
READ NEXT: 10 Best Future Stocks to Buy Under $10 and 12 Best Performing Semiconductor Stocks to Invest In.
Hedge Fund Resource Center